Terug
Ook genoteerd als
BMXXY
OTC
Dagbereik
€ 102,25
€ 115,00
52-Weeksbereik
€ 102,25
€ 152,00
Volume
868
50D / 200D Gem.
€ 117,87
/
€ 130,64
Vorige Slotkoers
€ 102,25
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 30,4 | 0,3 |
| P/B | 2,9 | 2,9 |
| ROE % | 9,6 | 3,7 |
| Net Margin % | 9,8 | 3,8 |
| Rev Growth 5Y % | 4,8 | 10,0 |
| D/E | 0,1 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 7,17
€ 7,01 – € 7,49
|
5,4 B | 1 |
| FY2029 |
€ 6,61
€ 6,46 – € 6,90
|
5,1 B | 1 |
| FY2028 |
€ 6,02
€ 5,89 – € 6,29
|
4,8 B | 1 |
Belangrijkste Punten
Revenue grew 4,77% annually over 5 years — modest growth
Debt/Equity of 0,11 — conservative balance sheet
Generating 452,83M in free cash flow
P/E of 30,38 — premium valuation
Cash machine — converts 113,96% of earnings into free cash flow
Capital efficient — spends only 8,24% of revenue on capex
Groei
Revenue Growth (5Y)
4,77%
Revenue (1Y)2,22%
Earnings (1Y)-8,06%
FCF Growth (3Y)105,62%
Kwaliteit
Return on Equity
9,57%
ROIC9,22%
Net Margin9,77%
Op. Margin13,79%
Veiligheid
Debt / Equity
0,11
Current Ratio2,39
Interest Coverage0,00
Waardering
P/E Ratio
30,38
P/B Ratio2,94
EV/EBITDA21,33
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2,22% | Revenue Growth (3Y) | 5,22% |
| Earnings Growth (1Y) | -8,06% | Earnings Growth (3Y) | 5,41% |
| Revenue Growth (5Y) | 4,77% | Earnings Growth (5Y) | -9,83% |
| Profitability | |||
| Revenue (TTM) | 4,07B | Net Income (TTM) | 397,35M |
| ROE | 9,57% | ROA | 7,13% |
| Gross Margin | 52,63% | Operating Margin | 13,79% |
| Net Margin | 9,77% | Free Cash Flow (TTM) | 452,83M |
| ROIC | 9,22% | FCF Growth (3Y) | 105,62% |
| Safety | |||
| Debt / Equity | 0,11 | Current Ratio | 2,39 |
| Interest Coverage | 0,00 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 30,38 | P/B Ratio | 2,94 |
| P/S Ratio | 2,97 | PEG Ratio | -3,99 |
| EV/EBITDA | 21,33 | Dividend Yield | 0,01% |
| Market Cap | 12,07B | Enterprise Value | 11,96B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4,07B | 3,98B | 3,67B | 3,59B | 3,38B |
| Net Income | 397,35M | 432,20M | 357,60M | 452,40M | 601,10M |
| EPS (Diluted) | 3,34 | 3,64 | 3,01 | 3,82 | 5,06 |
| Gross Profit | 2,14B | 2,22B | 2,06B | 2,01B | 2,00B |
| Operating Income | 560,99M | 588,80M | 439,00M | 587,20M | 784,30M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5,57B | 5,77B | 5,26B | 5,19B | 4,62B |
| Total Liabilities | 1,47B | 1,56B | 1,51B | 1,54B | 1,44B |
| Shareholders' Equity | 4,10B | 4,20B | 3,75B | 3,60B | 3,12B |
| Total Debt | 461,23M | 490,70M | 518,80M | 505,40M | 462,50M |
| Cash & Equivalents | 569,59M | 449,80M | 352,40M | 552,60M | 803,50M |
| Current Assets | 2,54B | 2,50B | 2,21B | 2,22B | 2,21B |
| Current Liabilities | 1,06B | 1,13B | 1,09B | 1,13B | 955,90M |